SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights Sale of INBRX-101 to Sanofi: In January 2024 , the Company announced that it entered into a definitive agreement with Aventis,... Read More